Virulent strains of the Newcastle disease virus (NDV) cause a highly contagious disease in domestic poultry that has resulted in major economic losses worldwide. Recurrent mutations in the viral genome and emersion of new strains are attributed to disease constant spread. These repeated episodes of infection have been questioning the efficacy of vaccines in use. However, recent advancement in molecular biology has enabled scientists to design recombinant vaccines which will be safer and provide long-lasting immunity. Thus, this study aims to analyze the Fusion glycoprotein (F0) of the NDV using a computational approach to identify highly antigenic and conserved epitopes that can be used for the development of a therapeutic peptide vaccine. The sequence of F0 glycoprotein of a virulent strain was subjected to software for the prediction of T cell and B cell epitopes. Epitopes were scrutinized based on their antigenicity, toxicity, conservancy, and topology. Cytotoxic T-lymphocytes (CTL) epitopes were checked for their ability to interact with chicken BF alleles through molecular docking. A 308 amino acid long MEV was constructed by joining cytotoxic T cell, helper T cell and interferon-gamma (IFN?) epitopes along with an adjuvant. The construct was found highly antigenic, stable, non-allergenic and stable. The ability of MEV to elicit host immune response is demonstrated by its strong binding affinity with chicken toll-like receptor (TLR-4). Our findings suggest that the designed MEV can act as a potent vaccine candidate against variant virulent NDV strains and can help in reducing the number of outbreaks.